- Gene Therapy Improves Vision in People With Inherited Blindness
- Parental Deaths to Guns, Drugs Harmed Nearly 100,000 U.S. Kids in 2020
- Money Worries Top Seniors’ List of Health-Related Concerns: Poll
- Scientists Developing Vaccine Against Present and Future COVID Viruses
- ERs Often Missing Epilepsy in Kids With ‘Non-Motor’ Seizures
- Parents of Infants With Cystic Fibrosis Often Feel Confused, Unsupported: Survey
- Avoid Some ‘Project Watson’ Dog Eye Wipes Due to Infection Danger
- New Test Might Alert Pregnant Women to Preeclampsia Danger
- Combo Therapy May Be Advance Against Liver Cancer
- How ‘Unruly’ Sports Parents Harm Their Kids’ Mental Health
Inhalation Anthrax Treatment Approved
Anthim (obiltoxaximab) has been approved by the U.S. Food and Drug Administration to treat inhalational anthrax, a rare disease stemming from infected animal products. Bacillus anthracis spores also pose a deadly bioterrorism threat if released intentionally.
Anthrax toxins can cause severe tissue damage and death, the FDA said Monday in a news release. Anthim, combined with certain antibacterial drugs, is designed to neutralize the toxins. The medication’s effectiveness was evaluated in studies conducted on animals, since it wasn’t ethical or feasible to conduct such trials with human volunteers, the agency said.
The drug’s safety was evaluated in 320 healthy human volunteers. The most common side effects included headache, itching, upper respiratory tract infection, cough, nasal congestion, hives and injection-site reactions including swelling, bruising and pain.
Anthim’s label includes a boxed warning of a potential severe and possibly fatal allergic reaction known as anaphylaxis. “However, given that anthrax is a very serious and often deadly condition, the benefit for treating anthrax is expected to outweigh this risk,” the FDA said.
Anthim was developed by Pine Brook, N.J.-based Elusys Therapeutics, with assistance from the U.S Department of Health and Human Services’ Biomedical Advanced Research and Development Authority.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.